<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id>
<journal-title-group>
<journal-title>PLOS Neglected Tropical Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pntd.0003996</article-id>
<article-id pub-id-type="publisher-id">PNTD-D-15-00710</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment</article-title>
<alt-title alt-title-type="running-head">Selamectin for Buruli Ulcer Treatment</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Scherr</surname>
<given-names>Nicole</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Pluschke</surname>
<given-names>Gerd</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Thompson</surname>
<given-names>Charles J.</given-names>
</name>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Ramón-García</surname>
<given-names>Santiago</given-names>
</name>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>University of Basel, Basel, Switzerland</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Microbiology and Immunology, Centre for Tuberculosis Research, Life Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Johnson</surname>
<given-names>Christian</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Fondation Raoul Follereau, FRANCE</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: NS GP CJT SRG. Performed the experiments: NS. Analyzed the data: NS SRG. Contributed reagents/materials/analysis tools: NS GP CJT SRG. Wrote the paper: SRG. Critically reviewed the paper: NS GP CJT.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ramon@mail.ubc.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>8</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2015</year>
</pub-date>
<volume>9</volume>
<issue>8</issue>
<elocation-id>e0003996</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>4</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>7</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Scherr et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pntd.0003996" xlink:type="simple"/>
<abstract>
<p>A comprehensive analysis was done to evaluate the potential use of anti-parasitic macrocyclic lactones (including avermectins and milbemycins) for Buruli ulcer (BU) therapy. A panel containing nearly all macrocyclic lactones used in human or in veterinary medicine was analyzed for activity <italic>in vitro</italic> against clinical isolates of <italic>Mycobacterium ulcerans</italic>. Milbemycin oxime and selamectin were the most active drugs against <italic>M</italic>. <italic>ulcerans</italic> with MIC values from 2 to 8 μg/mL and 2 to 4 μg/mL, respectively. In contrast, ivermectin and moxidectin, which are both in clinical use, showed no significant activity (MIC&gt; 32 μg/mL). Time-kill kinetic assays showed bactericidal activity of selamectin and <italic>in vitro</italic> pharmacodynamic studies demonstrated exposure-dependent activity. These data together with analyses of published pharmacokinetic information strongly suggest that selamectin is the most promising macrocyclic lactone for BU treatment.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author Summary</title>
<p>Buruli ulcer (BU) is a chronic debilitating mycobacterial disease of the skin and soft tissue caused by <italic>Mycobacterium ulcerans</italic>. It is mainly found in tropical regions and often linked to poverty. BU can be cured in most cases with the standard treatment, a combination of rifampicin and the injectable antibiotic streptomycin. However, new optimized treatment regimens are needed, especially to prepare for an eventual development of resistance to rifampicin, the most efficacious drug for BU therapy. Since traditional antibacterial drug discovery is not a practical option for BU, using approved drugs for alternative clinical indications would be a more economical and faster way to implement new anti-BU therapies. We reported previously that anti-parasitic avermectins are active against <italic>Mycobacterium tuberculosis</italic>. Here we show that some are also active <italic>in vitro</italic> against other mycobacterial species, including <italic>M</italic>. <italic>marinum</italic> and <italic>M</italic>. <italic>ulcerans</italic>. In this study, we undertook a comprehensive approach to evaluate additional macrocyclic lactones including compounds used in veterinary medicine. Based on our <italic>in vitro</italic> measurements of their activities and a literature review of their pharmacokinetic properties, we present strong arguments that selamectin is the avermectin with the highest potential for being repurposed for BU treatment.</p>
</abstract>
<funding-group>
<funding-statement>This work was supported by grants from the Canadian Institute of Health Research (MOP-82855) to CJT and the British Columbia Lung Association to SRG and CJT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="2"/>
<page-count count="10"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Buruli ulcer (BU), caused by <italic>Mycobacterium ulcerans</italic>, is a chronic debilitating disease of the skin and soft tissue. Although mortality is low, permanent disfigurement and disability is high [<xref rid="pntd.0003996.ref001" ref-type="bibr">1</xref>]. BU is mainly found in Africa, South America and the Western Pacific regions and is often linked to poverty. If detected early, BU can be cured in most cases with the standard treatment, a combination of rifampicin and the injectable antibiotic streptomycin [<xref rid="pntd.0003996.ref002" ref-type="bibr">2</xref>], without further adjunct surgical treatment required. However, new treatment regimens are needed to reduce the long median time to healing, treatment-related side effects, and the requirement for on-site health care workers to administer injections [<xref rid="pntd.0003996.ref003" ref-type="bibr">3</xref>]. Furthermore, an alternative drug treatment regimen would be required in the event that rifampicin resistant <italic>M</italic>. <italic>ulcerans</italic> strains would emerge in the clinic [<xref rid="pntd.0003996.ref004" ref-type="bibr">4</xref>].</p>
<p>Traditionally, the discovery of new antimicrobial drugs has focused on designing and screening for new compounds having novel targets, an approach that is costly in time and capital (up to ~$800M and 15–20 years) [<xref rid="pntd.0003996.ref005" ref-type="bibr">5</xref>]. This is not a viable option for BU, since most large pharmaceutical and biotech companies are primarily interested in blockbuster, broad spectrum antibacterial drugs [<xref rid="pntd.0003996.ref006" ref-type="bibr">6</xref>] rather than treatments for neglected tropical diseases. A faster and cheaper alternative to finding new BU treatments is drug repositioning, i.e. using approved drugs for alternative clinical indications [<xref rid="pntd.0003996.ref007" ref-type="bibr">7</xref>]. These drugs with known pharmacokinetic and safety profiles could be more rapidly evaluated in clinical trials [<xref rid="pntd.0003996.ref008" ref-type="bibr">8</xref>]. Such an approach would also allow for an easier drug introduction, since manufacturing and distribution infrastructures are already available.</p>
<p>In the course of screening clinically approved drugs to find new drug combinations for tuberculosis (TB) therapy, we discovered anti-mycobacterial activities of the avermectins, a class of macrocyclic lactones [<xref rid="pntd.0003996.ref009" ref-type="bibr">9</xref>]. Following up these findings, the <italic>in vitro</italic> activities of two clinically approved macrocyclic lactones (ivermectin and moxidectin) against <italic>M</italic>. <italic>ulcerans</italic> were recently reported [<xref rid="pntd.0003996.ref010" ref-type="bibr">10</xref>]. The avermectins are a family of macrocyclic lactone derivatives with potent anthelmintic properties, produced by the soil actinomycete <italic>Streptomyces avermitilis</italic>. Since avermectins are inactive against all other bacterial species tested [<xref rid="pntd.0003996.ref009" ref-type="bibr">9</xref>], oral administration would not affect healthful intestinal microbiome balances.</p>
<p>We undertook a comprehensive approach to evaluate additional macrocyclic lactones used in veterinary medicine. Based on our <italic>in vitro</italic> measurements of their activities and a literature review of their pharmacokinetic (PK) properties, we provide strong indications that selamectin (used in veterinary medicine), and not ivermectin (used in human medicine), is the avermectin with the highest potential for clinical efficacy to treat BU.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>Bacterial strains, general growth conditions and reagents</title>
<p><italic>M</italic>. <italic>marinum</italic> isolates (1704 and 1705; kindly provided by Dr. Julian Davies, University of British Columbia) were routinely propagated at 30°C in Middlebrook 7H9 broth (Difco) supplemented with 10% Middlebrook albumin-dextrose-catalase (ADC)(Difco), 0.2% glycerol and 0.05% (vol/vol) Tyloxapol or on Middlebrook 7H10 agar plates (Difco) supplemented with 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC)(Difco). <italic>M</italic>. <italic>ulcerans</italic> strains S1012, S1013 and S1047 (isolated in 2010 and 2011 from Cameroonian BU patients) were routinely grown in BacT/Alert culture bottles using enrichment medium (bioMérieux) or on Middlebrook 7H10 agar plates (Difco) supplemented with 10% (vol/vol) OADC. Macrocyclic lactones were purchased from the following providers: abamectin and doramectin (Sigma), emamectin and eprinomectin (LKT Labs), ivermectin (Alpha Diagnostic), milbemycin oxime (US Pharmacopeia), moxidectin and selamectin (European Pharmacopoeia).</p>
</sec>
<sec id="sec004">
<title>Drug susceptibility assays</title>
<p>Minimal Inhibitory Concentrations (MIC) were determined in 7H9 broth supplemented with 0.2% glycerol and 10% ADC (<italic>M</italic>. <italic>marinum</italic>) or 10% OADC (<italic>M</italic>. <italic>ulcerans</italic>) using two-fold serial dilutions of compounds in triplicate in polystyrene 96-well plates. MTT [3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] and resazurin were used as the bacterial growth indicators [<xref rid="pntd.0003996.ref011" ref-type="bibr">11</xref>] for <italic>M</italic>. <italic>marinum</italic> and <italic>M</italic>. <italic>ulcerans</italic>, respectively. For <italic>M</italic>. <italic>marinum</italic>, cultures were sampled (100 μL) at a cell density of 10<sup>5</sup> cells/mL and incubated in the presence of the drug for 3 days before addition of 25 μL of MTT (5 mg/mL). After further overnight incubation, 100 μL of 10% Sodium Lauryl Sulfate (SLS) were added to solubilize the formazan precipitate that indicates bacterial growth and the optical density at 580 nm (OD<sub>580</sub>) was then measured. In the case of <italic>M</italic>. <italic>ulcerans</italic>, 100 μL culture samples (OD<sub>600</sub> = 0.04) were incubated in the presence of the drug at 30°C for 8 days before addition of 20 μL of a resazurin solution (0.125 mg/mL), followed by overnight incubation at 37°C. Compound activity was determine by fluorescence measurements (λ = 540/588 nm). The lowest concentration of drug that inhibited 90% of the MTT or resazurin color conversion (IC<sub>90</sub>) was used to define MIC values.</p>
</sec>
<sec id="sec005">
<title><italic>M</italic>. <italic>ulcerans</italic> kill-kinetic assay</title>
<p>96-well polystyrene plates containing 200 μL per well of 7H9 broth supplemented with 10% OADC were inoculated in duplicate with <italic>M</italic>. <italic>ulcerans</italic> S1013 to a final OD<sub>600</sub> = 0.04 (ca. 10<sup>5</sup> cells/mL). Cultures were grown at 30°C in the presence of 0.5, 2, 4, 8, 16 and 32 μg/mL of selamectin (0.5, 1, 2, 4, 8 and 16 fold the selamectin MIC value, respectively) for 0, 3, 7, 14 and 21 days. At every time point, 100 μL of undiluted and ten-fold serial dilutions were plated on 7H10 agar. Colony-forming units for all plates were determined after 8 weeks of incubation at 30°C.</p>
</sec>
</sec>
<sec id="sec006" sec-type="results">
<title>Results</title>
<sec id="sec007">
<title>Comparative <italic>in vitro</italic> assays of macrocyclic lactones reveal that milbemycin oxime and selamectin are the most potent against <italic>M</italic>. <italic>ulcerans</italic></title>
<p>Eight commercially available macrocyclic lactones used in human and veterinary medicine were tested <italic>in vitro</italic> against <italic>M</italic>. <italic>ulcerans</italic> and <italic>M</italic>. <italic>marinum</italic>. Milbemycin oxime and selamectin were the most potent drugs against the <italic>M</italic>. <italic>ulcerans</italic> isolates (MIC in 2–4 μg/mL range). Emamectin and moxidectin had intermediate potency (MIC = ca. 32 μg/mL). While it was not possible to determine minimal inhibitory concentrations for ivermectin (IC<sub>90</sub> &gt;64 μg/mL), some inhibitory activity was observed in dose response studies. In contrast, most of the macrocyclic lactones showed activity against <italic>M</italic>. <italic>marinum</italic>, a faster growing phylogenetic progenitor of <italic>M</italic>. <italic>ulcerans</italic>, with milbemycin oxime being the most potent (<bold><xref rid="pntd.0003996.g001" ref-type="fig">Fig 1</xref> </bold>and <bold><xref rid="pntd.0003996.t001" ref-type="table">Table 1</xref></bold>).</p>
<fig id="pntd.0003996.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003996.g001</object-id>
<label>Fig 1</label>
<caption>
<title><italic>In vitro</italic> dose-response of the avermectins against <italic>M</italic>. <italic>ulcerans</italic> and <italic>M</italic>. <italic>marinum</italic>.</title>
<p>Values are the mean of activities against three <italic>M</italic>. <italic>ulcerans</italic> and two <italic>M</italic>. <italic>marinum</italic> clinical isolates (see <xref rid="pntd.0003996.t001" ref-type="table">Table 1</xref>) performed in triplicate. IC<sub>90</sub> and IC<sub>50</sub>, 90% and 50% reduction of resazurin or MTT color conversion, respectively.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003996.g001" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pntd.0003996.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003996.t001</object-id>
<label>Table 1</label> <caption><title>Antimicrobial activities of macrocyclic lactones against <italic>M</italic>. <italic>ulcerans</italic> and <italic>M</italic>. <italic>marinum</italic>.</title></caption>
<alternatives>
<graphic id="pntd.0003996.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003996.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1"> </th>
<th align="left" rowspan="1" colspan="1"> </th>
<th colspan="8" align="center" rowspan="1">MIC (μg/mL)<xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">Strains<xref rid="t001fn002" ref-type="table-fn"><sup>b</sup></xref></th>
<th align="left" rowspan="1" colspan="1"> </th>
<th align="center" rowspan="1" colspan="1">Abamectin</th>
<th align="center" rowspan="1" colspan="1">Doramectin</th>
<th align="center" rowspan="1" colspan="1">Emamectin</th>
<th align="center" rowspan="1" colspan="1">Eprinomectin</th>
<th align="center" rowspan="1" colspan="1">Ivermectin</th>
<th align="center" rowspan="1" colspan="1">Milbemycin oxime</th>
<th align="center" rowspan="1" colspan="1">Moxidectin</th>
<th align="center" rowspan="1" colspan="1">Selamectin</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>M</italic>. <italic>ulcerans</italic></td>
<td align="center" rowspan="1" colspan="1">S1012</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">8</td>
<td align="center" rowspan="1" colspan="1">16</td>
<td align="center" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">S1013</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">16–32</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">1–2</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">1–2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">S1047</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">&gt;64</td>
<td align="center" rowspan="1" colspan="1">4</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic>M</italic>. <italic>marinum</italic></td>
<td align="left" rowspan="1" colspan="1">1704</td>
<td align="center" rowspan="1" colspan="1">8–16</td>
<td align="center" rowspan="1" colspan="1">16–32</td>
<td align="center" rowspan="1" colspan="1">8</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">8</td>
<td align="center" rowspan="1" colspan="1">0.25–0.5</td>
<td align="center" rowspan="1" colspan="1">2–4</td>
<td align="center" rowspan="1" colspan="1">2–8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><italic> </italic></td>
<td align="left" rowspan="1" colspan="1">1705</td>
<td align="center" rowspan="1" colspan="1">8–16</td>
<td align="center" rowspan="1" colspan="1">32–64</td>
<td align="center" rowspan="1" colspan="1">8</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">8–16</td>
<td align="center" rowspan="1" colspan="1">0.25–0.5</td>
<td align="center" rowspan="1" colspan="1">2–4</td>
<td align="center" rowspan="1" colspan="1">4–8</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><sup>a</sup>Abamectin, doramectin, emamectin, eprinomectin, ivermectin and selamectin are avermectins; moxidectin and milbemycin oxime are milbemycins.</p></fn>
<fn id="t001fn002"><p><sup>b</sup>The resazurin and the MTT methods were used for <italic>M</italic>. <italic>ulcerans</italic> and <italic>M</italic>. <italic>marinum</italic>, respectively.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec008">
<title>Selamectin kills <italic>M</italic>. <italic>ulcerans</italic></title>
<p>The PK properties of selamectin (described below), together with its high <italic>in vitro</italic> activity against <italic>M</italic>. <italic>ulcerans</italic>, strongly indicated it as the most suitable avermectin for further evaluation as a potential new anti-BU treatment. To further characterize this potential new application, the <italic>in vitro</italic> pharmacodynamic (PD) parameters of selamectin were evaluated using kill-kinetic assays (<bold><xref rid="pntd.0003996.g002" ref-type="fig">Fig 2</xref></bold>). <italic>In vitro</italic> kill-kinetic curves for selamectin were obtained by plotting the number of CFU at every time point for every concentration of the drug (<bold><xref rid="pntd.0003996.g002" ref-type="fig">Fig 2A</xref></bold>). These experiments confirmed the MIC and dose-response data determined by reporters of metabolic activity (resazurin and the MTT; <bold><xref rid="pntd.0003996.t001" ref-type="table">Table 1</xref> </bold>and <bold><xref rid="pntd.0003996.g001" ref-type="fig">Fig 1</xref></bold>) and showed a sharp threshold of bactericidal activity above the MIC (2 μg/mL). We also used an alternative method to visualize kill kinetics: each selamectin concentration was multiplied by the time of exposure (C<sub>SEL</sub> x T<sub>days</sub>) and then divided by the MIC of selamectin to give the <italic>in vitro</italic> area under the concentration-time curve (AUC/MIC ratio), a standard measure of drug exposure (<bold><xref rid="pntd.0003996.g002" ref-type="fig">Fig 2B</xref></bold>). These analyses showed that just seven days of exposure were needed to observe the bactericidal activity of selamectin. The AUC/ MIC needed to achieve a bactericidal effect (4-log<sub>10</sub> CFU/ml reduction, 99.99% killing) required AUC/MIC ratios between 10 and 15. These ratios were comparable to those previously observed for <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pntd.0003996.ref009" ref-type="bibr">9</xref>]. In summary, these studies showed that the activity of selamectin against <italic>M</italic>. <italic>ulcerans</italic> is exposure-dependent; if a certain concentration is achieved, a bactericidal effect is observed by increasing the time of exposure but not by increasing dose concentrations. This information could have important implications when designing pre-clinical and clinical studies.</p>
<fig id="pntd.0003996.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003996.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Kill kinetics of selamectin against <italic>M</italic>. <italic>ulcerans</italic> S1013.</title>
<p>Dose response kill kinetic assays were plotted based on (<bold>A</bold>) drug concentration and (<bold>B</bold>) incubation time. AUC is the concentration of selamectin multiplied by the time of exposure (AUC = C<sub>SEL</sub> x T<sub>days</sub>). AUC, area under the curve. SEL, selamectin. Concentrations are in μg/m.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003996.g002" position="float" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec009" sec-type="conclusions">
<title>Discussion</title>
<p>The family of anthelmintic macrocyclic lactone drugs is one cornerstone of modern parasite control with annual world sales of US $850 million, indicating a well-established production and distribution pipeline. These drugs share a poly-cyclic lactone chemical moiety and can be divided in two sub-families: avermectins and milbemycins [<xref rid="pntd.0003996.ref012" ref-type="bibr">12</xref>]. Because members of this family of natural products have complex structures and specificity for parasites, only a few have been commercialized, mostly for veterinary medicine [<xref rid="pntd.0003996.ref013" ref-type="bibr">13</xref>]. Ivermectin is used to treat the human parasitic diseases onchocerciasis and lymphatic filariasis [<xref rid="pntd.0003996.ref014" ref-type="bibr">14</xref>]. Moxidectin was also recently evaluated for these indications in clinical trials [<xref rid="pntd.0003996.ref015" ref-type="bibr">15</xref>]. The potential use of ivermectin for TB treatment is questionable due to its neurotoxicity at high doses and the low exposure levels achieved using clinically approved doses [<xref rid="pntd.0003996.ref016" ref-type="bibr">16</xref>]. We analyzed available literature to compare the pharmacological properties of clinically approved drugs (ivermectin, moxidectin) to those with best <italic>in vitro</italic> activities against <italic>M</italic>. <italic>ulcerans</italic> (milbemycin oxime and selamectin)(<bold><xref rid="pntd.0003996.t002" ref-type="table">Table 2</xref></bold>). By integrating this information with <italic>in vitro</italic> data, we propose selamectin as the anthelmintic macrocyclic lactone with the highest potential for anti-BU therapy.</p>
<table-wrap id="pntd.0003996.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0003996.t002</object-id>
<label>Table 2</label> <caption><title>Pharmacokinetic meta-analysis summary of selected avermectins and milbemycins.</title></caption>
<alternatives>
<graphic id="pntd.0003996.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0003996.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Drug</th>
<th align="center" rowspan="1" colspan="1">Species</th>
<th align="center" rowspan="1" colspan="1">Dose (PO unless indicated)</th>
<th align="center" rowspan="1" colspan="1">Cmax (ng/mL)</th>
<th align="center" rowspan="1" colspan="1">T1/2 (days)</th>
<th align="center" rowspan="1" colspan="1">AUC (ng*h/ mL)</th>
<th align="center" rowspan="1" colspan="1">Theoretical AUC/MIC<xref rid="t002fn001" ref-type="table-fn"><sup>a</sup></xref></th>
<th align="center" rowspan="1" colspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Ivermectin</td>
<td align="center" rowspan="1" colspan="1">Humans</td>
<td align="center" rowspan="1" colspan="1">12 mg (165 μg/kg)</td>
<td align="center" rowspan="1" colspan="1">47</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref017" ref-type="bibr">17</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">30 mg (fast) (347–541 μg/kg)</td>
<td align="center" rowspan="1" colspan="1">85</td>
<td align="center" rowspan="1" colspan="1">19 h</td>
<td align="center" rowspan="1" colspan="1">2,819</td>
<td align="center" rowspan="1" colspan="1">0.04</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0003996.ref019" ref-type="bibr">19</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">30 mg (fed)</td>
<td align="center" rowspan="1" colspan="1">260</td>
<td align="center" rowspan="1" colspan="1">15 h</td>
<td align="center" rowspan="1" colspan="1">4,564</td>
<td align="center" rowspan="1" colspan="1">0.07</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">90 mg (1031–1466 μg/kg)</td>
<td align="center" rowspan="1" colspan="1">158</td>
<td align="center" rowspan="1" colspan="1">19 h</td>
<td align="center" rowspan="1" colspan="1">2,910</td>
<td align="center" rowspan="1" colspan="1">0.05</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">120 mg (1404–2000 μg/kg)</td>
<td align="center" rowspan="1" colspan="1">247</td>
<td align="center" rowspan="1" colspan="1">19 h</td>
<td align="center" rowspan="1" colspan="1">4,547</td>
<td align="center" rowspan="1" colspan="1">0.07</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Dogs</td>
<td align="center" rowspan="1" colspan="1">250 μg/kg</td>
<td align="center" rowspan="1" colspan="1">132</td>
<td align="center" rowspan="1" colspan="1">80 h</td>
<td align="center" rowspan="1" colspan="1">5,600</td>
<td align="center" rowspan="1" colspan="1">0.09</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref019" ref-type="bibr">19</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Horses</td>
<td align="center" rowspan="1" colspan="1">200 μg/kg</td>
<td align="center" rowspan="1" colspan="1">44</td>
<td align="center" rowspan="1" colspan="1">20 h</td>
<td align="center" rowspan="1" colspan="1">3,184</td>
<td align="center" rowspan="1" colspan="1">0.05</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref020" ref-type="bibr">20</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Mice (plasma)</td>
<td align="center" rowspan="1" colspan="1">0.2 mg/kg</td>
<td align="center" rowspan="1" colspan="1">20</td>
<td align="center" rowspan="1" colspan="1">9.3 h</td>
<td align="center" rowspan="1" colspan="1">573</td>
<td align="center" rowspan="1" colspan="1">0.01</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref021" ref-type="bibr">21</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Mice (lung)</td>
<td align="center" rowspan="1" colspan="1">0.2 mg/kg</td>
<td align="center" rowspan="1" colspan="1">20</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Mice</td>
<td align="center" rowspan="1" colspan="1">0.2 mg/kg</td>
<td align="center" rowspan="1" colspan="1">89.1</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">711.7</td>
<td align="center" rowspan="1" colspan="1">0.02</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref022" ref-type="bibr">22</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Moxidectin</td>
<td align="center" rowspan="1" colspan="1">Humans</td>
<td align="center" rowspan="1" colspan="1">3 mg (fast)</td>
<td align="center" rowspan="1" colspan="1">22.4</td>
<td align="center" rowspan="1" colspan="1">33.8</td>
<td align="center" rowspan="1" colspan="1">1,442</td>
<td align="center" rowspan="1" colspan="1">0.04</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref023" ref-type="bibr">23</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">9 mg (fast)</td>
<td align="center" rowspan="1" colspan="1">57.9</td>
<td align="center" rowspan="1" colspan="1">34.6</td>
<td align="center" rowspan="1" colspan="1">3,024</td>
<td align="center" rowspan="1" colspan="1">0.10</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">18 mg (fast)</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">22</td>
<td align="center" rowspan="1" colspan="1">5,856</td>
<td align="center" rowspan="1" colspan="1">0.18</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">36 mg (fast)</td>
<td align="center" rowspan="1" colspan="1">289</td>
<td align="center" rowspan="1" colspan="1">20.2</td>
<td align="center" rowspan="1" colspan="1">10,824</td>
<td align="center" rowspan="1" colspan="1">0.34</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">36 mg (fed)</td>
<td align="center" rowspan="1" colspan="1">296</td>
<td align="center" rowspan="1" colspan="1">25.7</td>
<td align="center" rowspan="1" colspan="1">14,976</td>
<td align="center" rowspan="1" colspan="1">0.46</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Dogs</td>
<td align="center" rowspan="1" colspan="1">250 μg/kg</td>
<td align="center" rowspan="1" colspan="1">234</td>
<td align="center" rowspan="1" colspan="1">621 h</td>
<td align="center" rowspan="1" colspan="1">11,800</td>
<td align="center" rowspan="1" colspan="1">0.36</td>
<td align="center" rowspan="1" colspan="1">ProHeart6 (Product profile)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Mice</td>
<td align="center" rowspan="1" colspan="1">0.2 mg/kg</td>
<td align="center" rowspan="1" colspan="1">47.4</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">643.7</td>
<td align="center" rowspan="1" colspan="1">0.02</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref022" ref-type="bibr">22</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Cattle (plasma)</td>
<td align="center" rowspan="1" colspan="1">0.2 mg/kg (s.c)</td>
<td align="center" rowspan="1" colspan="1">35.6</td>
<td align="center" rowspan="1" colspan="1">8.9</td>
<td align="center" rowspan="1" colspan="1">159 (ng.d/g)</td>
<td align="center" rowspan="1" colspan="1">0.004</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref024" ref-type="bibr">24</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Cattle (lung)</td>
<td align="center" rowspan="1" colspan="1">0.2 mg/kg (s.c)</td>
<td align="center" rowspan="1" colspan="1">63.7</td>
<td align="center" rowspan="1" colspan="1">9.1</td>
<td align="center" rowspan="1" colspan="1">298 (ng.d/g)</td>
<td align="center" rowspan="1" colspan="1">0.008</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Milbemycin oxime</td>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">0.25 mg/kg</td>
<td align="center" rowspan="1" colspan="1">79.33</td>
<td align="center" rowspan="1" colspan="1">11.09</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref025" ref-type="bibr">25</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">0.92 mg/kg (once monthly for 3 mo)</td>
<td align="center" rowspan="1" colspan="1">353</td>
<td align="center" rowspan="1" colspan="1">67.9</td>
<td align="center" rowspan="1" colspan="1">6,754.9</td>
<td align="center" rowspan="1" colspan="1">3.4</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref026" ref-type="bibr">26</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">1.19 mg/kg</td>
<td align="center" rowspan="1" colspan="1">152</td>
<td align="center" rowspan="1" colspan="1">50.2</td>
<td align="center" rowspan="1" colspan="1">3,620</td>
<td align="center" rowspan="1" colspan="1">1.8</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">1.10 mg/kg</td>
<td align="center" rowspan="1" colspan="1">199</td>
<td align="center" rowspan="1" colspan="1">58.2</td>
<td align="center" rowspan="1" colspan="1">5,165</td>
<td align="center" rowspan="1" colspan="1">2.6</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Selamectin</td>
<td align="center" rowspan="1" colspan="1">Dogs (male)</td>
<td align="center" rowspan="1" colspan="1">6 mg/kg (topical)</td>
<td align="center" rowspan="1" colspan="1">12.72</td>
<td align="center" rowspan="1" colspan="1">12.14</td>
<td align="center" rowspan="1" colspan="1">4,609</td>
<td align="center" rowspan="1" colspan="1">2.3</td>
<td align="center" rowspan="1" colspan="1">Stronghold (Product profile)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Dogs (female)</td>
<td align="center" rowspan="1" colspan="1">6 mg/kg (topical)</td>
<td align="center" rowspan="1" colspan="1">22.65</td>
<td align="center" rowspan="1" colspan="1">10.73</td>
<td align="center" rowspan="1" colspan="1">8,903</td>
<td align="center" rowspan="1" colspan="1">4.45</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Mice (plasma)</td>
<td align="center" rowspan="1" colspan="1">12 mg/kg</td>
<td align="center" rowspan="1" colspan="1">3,714</td>
<td align="center" rowspan="1" colspan="1">5.5</td>
<td align="center" rowspan="1" colspan="1">62,285.7</td>
<td align="center" rowspan="1" colspan="1">31.14</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref021" ref-type="bibr">21</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Mice (lung)</td>
<td align="center" rowspan="1" colspan="1">12 mg/kg</td>
<td align="center" rowspan="1" colspan="1">7,500</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Rats</td>
<td align="center" rowspan="1" colspan="1">10 mg/kg</td>
<td align="center" rowspan="1" colspan="1">&gt;1,000</td>
<td align="center" rowspan="1" colspan="1">10.3 h</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">Stronghold (Product profile)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Dogs</td>
<td align="center" rowspan="1" colspan="1">24 mg/kg</td>
<td align="center" rowspan="1" colspan="1">7,630</td>
<td align="center" rowspan="1" colspan="1">45.7 h</td>
<td align="center" rowspan="1" colspan="1">227,901</td>
<td align="center" rowspan="1" colspan="1">113.95</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref027" ref-type="bibr">27</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">24 mg/kg (topical)</td>
<td align="center" rowspan="1" colspan="1">86.5</td>
<td align="center" rowspan="1" colspan="1">266</td>
<td align="center" rowspan="1" colspan="1">15229</td>
<td align="center" rowspan="1" colspan="1">7.61</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">95 mg/kg</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">nd</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref028" ref-type="bibr">28</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">Cats</td>
<td align="center" rowspan="1" colspan="1">24 mg/kg</td>
<td align="center" rowspan="1" colspan="1">11,929</td>
<td align="center" rowspan="1" colspan="1">97.7</td>
<td align="center" rowspan="1" colspan="1">1,109,933</td>
<td align="center" rowspan="1" colspan="1">554.97</td>
<td align="center" rowspan="1" colspan="1">[<xref rid="pntd.0003996.ref027" ref-type="bibr">27</xref>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1"/>
<td align="center" rowspan="1" colspan="1">24 mg/kg (topical)</td>
<td align="center" rowspan="1" colspan="1">5,513</td>
<td align="center" rowspan="1" colspan="1">198</td>
<td align="center" rowspan="1" colspan="1">743,349</td>
<td align="center" rowspan="1" colspan="1">371.67</td>
<td align="center" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><sup>a</sup>Theoretical AUC/MIC was calculated based on our <italic>in vitro</italic> MIC values of the avermectins against <italic>M</italic>. <italic>ulcerans</italic>. MIC values (in ng/mL) used for calculations were: ivermectin, 64,000; moxidectin, 32,000; milbemycin oxime, 2,000, and selamectin: 2,000.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>In invertebrate nematodes, avermectins specifically bind to glutamate-gated chloride channels present in nerve and muscle cells, causing paralysis and reduced ability to reproduce. In general, macrocyclic lactones have a high margin of safety in mammals because P-glycoproteins (P-gp) or other types of efflux pumps, highly expressed at the blood–brain barrier, efficiently restrict their penetration into the central nervous system. In fact, dogs lacking the MDR1 efflux pump, such as collies, have much less tolerance for treatment with an array of avermectin compounds [<xref rid="pntd.0003996.ref029" ref-type="bibr">29</xref>]. In contrast, milbemycin oxime, selamectin, and moxidectin can be safely administered at therapeutic doses to dogs having a homozygous MDR1 mutation without any signs of toxicosis [<xref rid="pntd.0003996.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0003996.ref028" ref-type="bibr">28</xref>].</p>
<p>PK and toxicological profiles of the clinically used macrocyclic lactones (ivermectin and moxidectin) have been studied extensively. Using standard dosages for onchocerciasis treatment in humans, ivermectin is extremely well tolerated, effective, orally active, and associated with long-term safety at the current clinical dose (single dose of 12 mg) [<xref rid="pntd.0003996.ref017" ref-type="bibr">17</xref>]. Clinical studies have shown that it is safe in humans at doses up to 10-fold higher; however, further increased dosage provokes severe neurotoxicity [<xref rid="pntd.0003996.ref018" ref-type="bibr">18</xref>]. To catalyze application of ivermectin’s therapeutic potential in needy areas throughout the world, Merck &amp; Co. has donated it for over 20 years to treat patients with river blindness, human onchocerciasis, and lymphatic filariasis [<xref rid="pntd.0003996.ref014" ref-type="bibr">14</xref>]. In the case of moxidectin, single doses of up to 36 mg were safe in humans, but not doses of 54 mg [<xref rid="pntd.0003996.ref023" ref-type="bibr">23</xref>].</p>
<p>The extensive use of macrocyclic lactones in veterinary medicine has generated valuable pharmacological data that could guide selection of these drugs and facilitate their use in humans. Milbemycin oxime is a broad-spectrum intestinal anti-parasitic drug used to treat roundworm, hookworm and tapeworms in cats and dogs; it is also reported to be safer than ivermectin [<xref rid="pntd.0003996.ref012" ref-type="bibr">12</xref>]. Administered routinely at a dose of 0.25 mg/kg, it showed no signs of toxicity [<xref rid="pntd.0003996.ref025" ref-type="bibr">25</xref>]. Although LD<sub>50</sub> values after oral administration in dogs are higher than 200 mg/kg, a single dose of 3.8 mg/kg was reported to cause reversible neurological signs (trembling, ataxia) in dogs [<xref rid="pntd.0003996.ref030" ref-type="bibr">30</xref>]. In contrast, selamectin has fewer neurological side effects, and can be administered topically, subcutaneously, or orally to treat a variety of ecto- and endo-parasitic infections in cats and dogs. It is the drug of choice in avermectin-sensitive collies since it has no adverse effects [REVOLUTION—fact sheet]. A toxicity study in female CD1 mice found that selamectin was well tolerated at up to 300 mg/kg body weight (bw), while similar doses of milbemycin oxime were toxic [<xref rid="pntd.0003996.ref031" ref-type="bibr">31</xref>]. In the case of milbemycin, doses up to 24 mg/kg bw were safe in cats and dogs [<xref rid="pntd.0003996.ref027" ref-type="bibr">27</xref>] and one study reported that doses up to 94 mg/kg bw were safe in dogs [<xref rid="pntd.0003996.ref028" ref-type="bibr">28</xref>]. In addition, a 3-month repeated dose toxicity study in dogs found an oral dose of 40 mg/kg/day to be safe [<xref rid="pntd.0003996.ref028" ref-type="bibr">28</xref>]. Extrapolated to humans, this corresponds to a dose of 2,800 mg/day (for a 70 kg adult). Confirming this extrapolation, the LD<sub>50</sub> in rats and mice could not be demonstrated and it was higher than 1,600 mg/kg bw [Stronghold (selamectin)—Product profile].</p>
<p>Based on established clinical experience in humans at low dosages, Omansen <italic>et al</italic>. [<xref rid="pntd.0003996.ref010" ref-type="bibr">10</xref>] chose to study the anti-mycobacterial activities of ivermectin and moxidectin. They reported MIC values between 4 and 8 μg/mL against <italic>M</italic>. <italic>ulcerans</italic> and inactivity (MIC ≥32 μg/mL) against <italic>M</italic>. <italic>marinum</italic>. We confirmed the activities of macrocyclic lactones, but found different specificities against bacterial isolates representing these two species (<bold><xref rid="pntd.0003996.t001" ref-type="table">Table 1</xref> </bold>and <bold><xref rid="pntd.0003996.g001" ref-type="fig">Fig 1</xref></bold>). In contrast to analyses reported by Omansen <italic>et al</italic>. [<xref rid="pntd.0003996.ref010" ref-type="bibr">10</xref>], we detected little or no activity of ivermectin and moxidectin against <italic>M</italic>. <italic>ulcerans</italic> isolates but they were active against <italic>M</italic>. <italic>marinum</italic> strains. Such discrepancies could reflect variations in methodology. While Omansen <italic>et al</italic>. used Mycobacteria Growth Indicator Tubes (MGIT) and bioluminescence assays for their inhibitions assays [<xref rid="pntd.0003996.ref010" ref-type="bibr">10</xref>], we performed metabolic-based activity assays in liquid cultures grown in 96 well plates. Subtle differences in methodology are known to play a critical role in quantification of the anti-mycobacterial activity of ivermectin [<xref rid="pntd.0003996.ref016" ref-type="bibr">16</xref>].</p>
<p>Our <italic>in vitro</italic> results can be integrated with available PK data to predict which drug would be more suitable for anti-BU therapy. While no human data are available for milbemycin oxime and selamectin, extensive pharmacological data from animal studies provide valuable information to accelerate clinical testing. Standard oral doses (in μg/kg bw range) of ivermectin, moxidectin and milbemycin oxime used to treat helminths in humans only achieve low concentrations in the plasma (ng/mL range). Area Under the Curve (AUC) values for moxidectin and milbemycin oxime are higher than those of ivermectin, mainly due to their extended residence times (higher half-life). However, the much higher doses needed to achieve concentrations sufficient to kill mycobacteria might not be possible due to toxicity. In contrast, selamectin toxicity is negligible at comparable doses. Standard dose administration of selamectin is in the mg/kg bw range (versus μg/kg bw) and doses as high as 95 mg/kg bw have been administered without any side effects [<xref rid="pntd.0003996.ref028" ref-type="bibr">28</xref>]. The ability to deliver such high doses without toxicity is also reflected in the elevated concentrations of selamectin that can be achieved in the plasma. These concentrations in the μg/mL range are several fold higher than MIC values against <italic>M</italic>. <italic>ulcerans</italic> [<xref rid="pntd.0003996.ref021" ref-type="bibr">21</xref>,<xref rid="pntd.0003996.ref027" ref-type="bibr">27</xref>] which, together with a long half-life (in days), allows for high AUC values. In fact, AUC/MIC values are the most predictable PK/PD parameter for the anti-mycobacterial activity of the avermectins [<xref rid="pntd.0003996.ref009" ref-type="bibr">9</xref>]. Similarly, AUC/MIC ratios between 10 and 15 are also needed for bactericidal activity against <italic>M</italic>. <italic>ulcerans</italic> (<bold><xref rid="pntd.0003996.g002" ref-type="fig">Fig 2B</xref></bold>). Thus, when theoretical AUC/MIC values were calculated by integrating data from available PK literature with those from our <italic>in vitro</italic> data, only selamectin was predicted to have therapeutic activity against <italic>M</italic>. <italic>ulcerans</italic> (<bold><xref rid="pntd.0003996.t002" ref-type="table">Table 2</xref></bold>)(nb, calculations based on the lower <italic>in vitro</italic> MIC measurement reported by Omamsen et al. [<xref rid="pntd.0003996.ref010" ref-type="bibr">10</xref>] generated the same conclusion). We would also like to point out that when we made corresponding calculations based on <italic>in vitro</italic> MIC data for <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pntd.0003996.ref009" ref-type="bibr">9</xref>], selamectin would also be the avermectin of choice for tuberculosis therapy.</p>
<p>A synergistic interaction between rifampicin and ivermectin against <italic>M</italic>. <italic>ulcerans</italic> has also been reported [<xref rid="pntd.0003996.ref010" ref-type="bibr">10</xref>]. Rifampicin is the cornerstone drug for BU treatment. Thus, co-administration of rifampicin with any synergistic, orally available drug would be ideal. Rifampicin is an inducer of the P-gp and other transporters. P-gp protects mammals not only by excluding macrocyclic lactones from the central nervous system, but also by limiting the uptake of compounds from the gastrointestinal tract and by promoting their excretion in the liver, kidney, and intestine. While ivermectin is a good P-gp substrate, thus further reducing available levels of this drug, selamectin is a poorer P-gp substrate [<xref rid="pntd.0003996.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0003996.ref021" ref-type="bibr">21</xref>] and its plasma levels would be affected to a lesser extent allowing for a potential co-administration with rifampicin.</p>
<p>In summary, drug repositioning is an interesting avenue to provide new treatments for neglected diseases. We have tested the family of commercially available macrocyclic lactones against <italic>M</italic>. <italic>ulcerans</italic> and <italic>M</italic>. <italic>marinum</italic> and demonstrated that milbemycin oxime and selamectin are the most active drugs (MIC = 2 μg/mL). Integrating these values with information gathered in a literature review of the pharmacological properties (toxicity and PK/PD profiles) of ivermectin, moxidectin, milbemycin oxime and selamectin, revealed selamectin as the most promising avermectin candidate for anti-BU treatment. Although selamectin is not approved for use in humans, extensive information is available on its pharmacological properties in animals, thus facilitating its progression into clinical trials. These would be warranted if its activity could be validated using <italic>in vivo</italic> models of <italic>M</italic>. <italic>ulcerans</italic> infection. Pre-clinical and clinical development of any drug is a task that one research group cannot achieve alone. Thus, we urge collaboration among the research communities, pharmaceutical companies, and non-governmental organizations to validate the potential of macrocyclic lactones, especially selamectin, as a new anti-BU treatment.</p>
</sec>
</body>
<back>
<ack>
<p>We thank Dr. Gaye Sweet for technical support and compound management and Dr. Julian Davies for kindly providing the <italic>M</italic>. <italic>marinum</italic> isolates. We are also grateful to Jennifer Dent, Roopa Ramamoorthi and Katy Graef from BIO Ventures for Global Health (BVGH) for catalyzing this collaboration through WIPO Re:Search.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0003996.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ellen</surname> <given-names>D.E.</given-names></name> <etal>et al</etal>. <article-title>Assessment of functional limitations caused by <italic>Mycobacterium ulcerans</italic> infection: towards a Buruli ulcer functional limitation score</article-title>. <source>Tropical medicine &amp; international health: TM &amp; IH</source> <volume>8</volume>, <fpage>90</fpage>–<lpage>96</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref002"><label>2</label><mixed-citation publication-type="other" xlink:type="simple"><ext-link ext-link-type="uri" xlink:href="http://www.who.int/buruli/en/" xlink:type="simple">http://www.who.int/buruli/en/</ext-link></mixed-citation></ref>
<ref id="pntd.0003996.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nienhuis</surname> <given-names>W.A.</given-names></name> <etal>et al</etal>. <article-title>Antimicrobial treatment for early, limited <italic>Mycobacterium ulcerans</italic> infection: a randomised controlled trial</article-title>. <source>Lancet</source> <volume>375</volume>, <fpage>664</fpage>–<lpage>672</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marsollier</surname> <given-names>L.</given-names></name> <etal>et al</etal>. <article-title>Isolation of three <italic>Mycobacterium ulcerans</italic> strains resistant to rifampin after experimental chemotherapy of mice</article-title>. <source>Antimicrob Agents Chemother</source> <volume>47</volume>, <fpage>1228</fpage>–<lpage>1232</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DiMasi</surname> <given-names>J.A.</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>R.W.</given-names></name> &amp; <name name-style="western"><surname>Grabowski</surname> <given-names>H.G.</given-names></name> <article-title>The price of innovation: new estimates of drug development costs</article-title>. <source>J Health Econ</source> <volume>22</volume>, <fpage>151</fpage>–<lpage>185</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Payne</surname> <given-names>D.J.</given-names></name>, <name name-style="western"><surname>Gwynn</surname> <given-names>M.N.</given-names></name>, <name name-style="western"><surname>Holmes</surname> <given-names>D.J.</given-names></name> &amp; <name name-style="western"><surname>Pompliano</surname> <given-names>D.L.</given-names></name> <article-title>Drugs for bad bugs: confronting the challenges of antibacterial discovery</article-title>. <source>Nat Rev Drug Discov</source> <volume>6</volume>, <fpage>29</fpage>–<lpage>40</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramon-Garcia</surname> <given-names>S.</given-names></name> <etal>et al</etal>. <article-title>Synergistic drug combinations for tuberculosis therapy identified by a novel high throughput screen</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2011</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chong</surname> <given-names>C.R.</given-names></name> &amp; <name name-style="western"><surname>Sullivan</surname> <given-names>D.J.</given-names> <suffix>Jr.</suffix></name> <article-title>New uses for old drugs</article-title>. <source>Nature</source> <volume>448</volume>, <fpage>645</fpage>–<lpage>646</lpage> (<year>2007</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lim</surname> <given-names>L.E.</given-names></name> <etal>et al</etal>. <article-title>Anthelmintic avermectins kill <italic>Mycobacterium tuberculosis</italic>, including multidrug-resistant clinical strains</article-title>. <source>Antimicrob Agents Chemother</source> <volume>57</volume>, <fpage>1040</fpage>–<lpage>1046</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Omansen</surname> <given-names>T.F.</given-names></name> <etal>et al</etal>. <article-title>In-vitro activity of avermectins against <italic>Mycobacterium ulcerans</italic></article-title>. <source>PLoS neglected tropical diseases</source> <volume>9</volume>, <fpage>e0003549</fpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Montoro</surname> <given-names>E.</given-names></name> <etal>et al</etal>. <article-title>Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>J Antimicrob Chemother</source> <volume>55</volume>, <fpage>500</fpage>–<lpage>505</lpage> (<year>2005</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Prichard</surname> <given-names>R.</given-names></name>, <name name-style="western"><surname>Menez</surname> <given-names>C.</given-names></name> &amp; <name name-style="western"><surname>Lespine</surname> <given-names>A.</given-names></name> <article-title>Moxidectin and the avermectins: Consanguinity but not identity</article-title>. <source>International journal for parasitology</source>. <source>Drugs and drug resistance</source> <volume>2</volume>, <fpage>134</fpage>–<lpage>153</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thuan</surname> <given-names>N.H.</given-names></name>, <name name-style="western"><surname>Pandey</surname> <given-names>R.P.</given-names></name> &amp; <name name-style="western"><surname>Sohng</surname> <given-names>J.K.</given-names></name> <article-title>Recent advances in biochemistry and biotechnological synthesis of avermectins and their derivatives</article-title>. <source>Applied microbiology and biotechnology</source> <volume>98</volume>, <fpage>7747</fpage>–<lpage>7759</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Omura</surname> <given-names>S.</given-names></name> &amp; <name name-style="western"><surname>Crump</surname> <given-names>A.</given-names></name> <article-title>The life and times of ivermectin—a success story. <italic>Nature reviews</italic></article-title>. <source>Microbiology</source> <volume>2</volume>, <fpage>984</fpage>–<lpage>989</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref015"><label>15</label><mixed-citation publication-type="other" xlink:type="simple"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00790998" xlink:type="simple">https://clinicaltrials.gov/ct2/show/NCT00790998</ext-link></mixed-citation></ref>
<ref id="pntd.0003996.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramon-Garcia</surname> <given-names>S.</given-names></name> <etal>et al</etal>. <article-title>Measurements of the <italic>in vitro</italic> anti-mycobacterial activity of ivermectin are method-dependent</article-title>. <source>J Antimicrob Chemother</source> <volume>69</volume>, <fpage>1723</fpage>–<lpage>1724</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guzzo</surname> <given-names>C.A.</given-names></name> <etal>et al</etal>. <article-title>Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects</article-title>. <source>Journal of clinical pharmacology</source> <volume>42</volume>, <fpage>1122</fpage>–<lpage>1133</lpage> (<year>2002</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gonzalez Canga</surname> <given-names>A.</given-names></name> <etal>et al</etal>. <article-title>The pharmacokinetics and interactions of ivermectin in humans—a mini-review</article-title>. <source>The AAPS journal</source> <volume>10</volume>, <fpage>42</fpage>–<lpage>46</lpage> (<year>2008</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Daurio</surname> <given-names>C.P.</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>E.N.</given-names></name>, <name name-style="western"><surname>Jeffcoat</surname> <given-names>A.R.</given-names></name> &amp; <name name-style="western"><surname>Skelly</surname> <given-names>B.J.</given-names></name> <article-title>Bioavailability of ivermectin administered orally to dogs</article-title>. <source>Veterinary research communications</source> <volume>16</volume>, <fpage>125</fpage>–<lpage>130</lpage> (<year>1992</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perez</surname> <given-names>R.</given-names></name> <etal>et al</etal>. <article-title>Pharmacokinetics of doramectin and ivermectin after oral administration in horses</article-title>. <source>Veterinary journal</source> <volume>163</volume>, <fpage>161</fpage>–<lpage>167</lpage> (<year>2002</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Geyer</surname> <given-names>J.</given-names></name>, <name name-style="western"><surname>Gavrilova</surname> <given-names>O.</given-names></name> &amp; <name name-style="western"><surname>Petzinger</surname> <given-names>E.</given-names></name> <article-title>Brain penetration of ivermectin and selamectin in <italic>mdr1a</italic>,<italic>b</italic> P-glycoprotein- and <italic>bcrp-</italic> deficient knockout mice</article-title>. <source>Journal of veterinary pharmacology and therapeutics</source> <volume>32</volume>, <fpage>87</fpage>–<lpage>96</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kiki-Mvouaka</surname> <given-names>S.</given-names></name> <etal>et al</etal>. <article-title>Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice</article-title>. <source>Drug metabolism and disposition: the biological fate of chemicals</source> <volume>38</volume>, <fpage>573</fpage>–<lpage>580</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cotreau</surname> <given-names>M.M.</given-names></name> <etal>et al</etal>. <article-title>The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans</article-title>. <source>Journal of clinical pharmacology</source> <volume>43</volume>, <fpage>1108</fpage>–<lpage>1115</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lifschitz</surname> <given-names>A.</given-names></name> <etal>et al</etal>. <article-title>Moxidectin in cattle: correlation between plasma and target tissues disposition</article-title>. <source>Journal of veterinary pharmacology and therapeutics</source> <volume>22</volume>, <fpage>266</fpage>–<lpage>273</lpage> (<year>1999</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>Q.</given-names></name> <etal>et al</etal>. <article-title>An LC-MS method for determination of milbemycin oxime in dog plasma</article-title>. <source>Journal of chromatographic science</source> <volume>52</volume>, <fpage>999</fpage>–<lpage>1004</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Holmstrom</surname> <given-names>S.D.</given-names></name>, <name name-style="western"><surname>Totten</surname> <given-names>M.L.</given-names></name>, <name name-style="western"><surname>Newhall</surname> <given-names>K.B.</given-names></name>, <name name-style="western"><surname>Qiao</surname> <given-names>M.</given-names></name> &amp; <name name-style="western"><surname>Riggs</surname> <given-names>K.L.</given-names></name> <article-title>Pharmacokinetics of spinosad and milbemycin oxime administered in combination and separately per os to dogs</article-title>. <source>Journal of veterinary pharmacology and therapeutics</source> <volume>35</volume>, <fpage>351</fpage>–<lpage>364</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sarasola</surname> <given-names>P.</given-names></name> <etal>et al.</etal> <article-title>Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs</article-title>. <source>Journal of veterinary pharmacology and therapeutics</source> <volume>25</volume>, <fpage>265</fpage>–<lpage>272</lpage> (<year>2002</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Novotny</surname> <given-names>M.J.</given-names></name> <etal>et al</etal>. <article-title>Safety of selamectin in dogs</article-title>. <source>Veterinary parasitology</source> <volume>91</volume>, <fpage>377</fpage>–<lpage>391</lpage> (<year>2000</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shoop</surname> <given-names>W.L.</given-names></name>, <name name-style="western"><surname>Mrozik</surname> <given-names>H.</given-names></name> &amp; <name name-style="western"><surname>Fisher</surname> <given-names>M.H.</given-names></name> <article-title>Structure and activity of avermectins and milbemycins in animal health</article-title>. <source>Veterinary parasitology</source> <volume>59</volume>, <fpage>139</fpage>–<lpage>156</lpage> (<year>1995</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Jaham</surname> <given-names>C.</given-names></name> &amp; <name name-style="western"><surname>Henry</surname> <given-names>C.J.</given-names></name> <article-title>Treatment of canine sarcoptic mange using milbemycin oxime</article-title>. <source>The Canadian veterinary journal. La revue veterinaire canadienne</source> <volume>36</volume>, <fpage>42</fpage>–<lpage>43</lpage> (<year>1995</year>).</mixed-citation></ref>
<ref id="pntd.0003996.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bishop</surname> <given-names>B.F.</given-names></name> <etal>et al</etal>. <article-title>Selamectin: a novel broad-spectrum endectocide for dogs and cats</article-title>. <source>Veterinary parasitology</source> <volume>91</volume>, <fpage>163</fpage>–<lpage>176</lpage> (<year>2000</year>).</mixed-citation></ref>
</ref-list>
</back>
</article>